Cargando…

A novel necroptosis-related LncRNA signature for prediction of prognosis and therapeutic responses of head and neck squamous cell carcinoma

Background: Long non-coding RNAs (lncRNAs) play an essential role in the occurrence and prognosis of tumors, and it has great potential as biomarkers of tumors. However, the roles of Necroptosis-related lncRNA (NRLs) in Head and neck squamous cell carcinoma (HNSCC) remain elusive. Methods: We compre...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Zilu, Yang, Wenhan, Zhu, Lei, Liu, Wanyu, Wang, Yudong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395581/
https://www.ncbi.nlm.nih.gov/pubmed/36016575
http://dx.doi.org/10.3389/fphar.2022.963072
_version_ 1784771729062625280
author Meng, Zilu
Yang, Wenhan
Zhu, Lei
Liu, Wanyu
Wang, Yudong
author_facet Meng, Zilu
Yang, Wenhan
Zhu, Lei
Liu, Wanyu
Wang, Yudong
author_sort Meng, Zilu
collection PubMed
description Background: Long non-coding RNAs (lncRNAs) play an essential role in the occurrence and prognosis of tumors, and it has great potential as biomarkers of tumors. However, the roles of Necroptosis-related lncRNA (NRLs) in Head and neck squamous cell carcinoma (HNSCC) remain elusive. Methods: We comprehensively analyzed the gene expression and clinical information of 964 HNSCC in four cohorts. LASSO regression was utilized to construct a necroptosis-related lncRNA prognosis signature (NLPS). We used univariate and multivariate regression to assess the independent prognostic value of NLPS. Based on the optimal cut-off, patients were divided into high- and low-risk groups. In addition, the immune profile, multi-omics alteration, and pharmacological landscape of NLPS were further revealed. Results: A total of 21 NRLs associated with survival were identified by univariate regression in four cohorts. We constructed and validated a best prognostic model (NLPS). Compared to the low-risk group, patients in the high group demonstrated a more dismal prognosis. After adjusting for clinical features by multivariate analysis, NLPS still displayed independent prognostic value. Additionally, further analysis found that patients in the low-risk group showed more abundant immune cell infiltration and immunotherapy response. In contrast, patients in the high-risk group were more sensitive to multiple chemotherapeutic agents. Conclusion: As a promising tool, the establishment of NLPS provides guidance and assistance in the clinical management and personalized treatment of HNSCC.
format Online
Article
Text
id pubmed-9395581
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93955812022-08-24 A novel necroptosis-related LncRNA signature for prediction of prognosis and therapeutic responses of head and neck squamous cell carcinoma Meng, Zilu Yang, Wenhan Zhu, Lei Liu, Wanyu Wang, Yudong Front Pharmacol Pharmacology Background: Long non-coding RNAs (lncRNAs) play an essential role in the occurrence and prognosis of tumors, and it has great potential as biomarkers of tumors. However, the roles of Necroptosis-related lncRNA (NRLs) in Head and neck squamous cell carcinoma (HNSCC) remain elusive. Methods: We comprehensively analyzed the gene expression and clinical information of 964 HNSCC in four cohorts. LASSO regression was utilized to construct a necroptosis-related lncRNA prognosis signature (NLPS). We used univariate and multivariate regression to assess the independent prognostic value of NLPS. Based on the optimal cut-off, patients were divided into high- and low-risk groups. In addition, the immune profile, multi-omics alteration, and pharmacological landscape of NLPS were further revealed. Results: A total of 21 NRLs associated with survival were identified by univariate regression in four cohorts. We constructed and validated a best prognostic model (NLPS). Compared to the low-risk group, patients in the high group demonstrated a more dismal prognosis. After adjusting for clinical features by multivariate analysis, NLPS still displayed independent prognostic value. Additionally, further analysis found that patients in the low-risk group showed more abundant immune cell infiltration and immunotherapy response. In contrast, patients in the high-risk group were more sensitive to multiple chemotherapeutic agents. Conclusion: As a promising tool, the establishment of NLPS provides guidance and assistance in the clinical management and personalized treatment of HNSCC. Frontiers Media S.A. 2022-08-09 /pmc/articles/PMC9395581/ /pubmed/36016575 http://dx.doi.org/10.3389/fphar.2022.963072 Text en Copyright © 2022 Meng, Yang, Zhu, Liu and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Meng, Zilu
Yang, Wenhan
Zhu, Lei
Liu, Wanyu
Wang, Yudong
A novel necroptosis-related LncRNA signature for prediction of prognosis and therapeutic responses of head and neck squamous cell carcinoma
title A novel necroptosis-related LncRNA signature for prediction of prognosis and therapeutic responses of head and neck squamous cell carcinoma
title_full A novel necroptosis-related LncRNA signature for prediction of prognosis and therapeutic responses of head and neck squamous cell carcinoma
title_fullStr A novel necroptosis-related LncRNA signature for prediction of prognosis and therapeutic responses of head and neck squamous cell carcinoma
title_full_unstemmed A novel necroptosis-related LncRNA signature for prediction of prognosis and therapeutic responses of head and neck squamous cell carcinoma
title_short A novel necroptosis-related LncRNA signature for prediction of prognosis and therapeutic responses of head and neck squamous cell carcinoma
title_sort novel necroptosis-related lncrna signature for prediction of prognosis and therapeutic responses of head and neck squamous cell carcinoma
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9395581/
https://www.ncbi.nlm.nih.gov/pubmed/36016575
http://dx.doi.org/10.3389/fphar.2022.963072
work_keys_str_mv AT mengzilu anovelnecroptosisrelatedlncrnasignatureforpredictionofprognosisandtherapeuticresponsesofheadandnecksquamouscellcarcinoma
AT yangwenhan anovelnecroptosisrelatedlncrnasignatureforpredictionofprognosisandtherapeuticresponsesofheadandnecksquamouscellcarcinoma
AT zhulei anovelnecroptosisrelatedlncrnasignatureforpredictionofprognosisandtherapeuticresponsesofheadandnecksquamouscellcarcinoma
AT liuwanyu anovelnecroptosisrelatedlncrnasignatureforpredictionofprognosisandtherapeuticresponsesofheadandnecksquamouscellcarcinoma
AT wangyudong anovelnecroptosisrelatedlncrnasignatureforpredictionofprognosisandtherapeuticresponsesofheadandnecksquamouscellcarcinoma
AT mengzilu novelnecroptosisrelatedlncrnasignatureforpredictionofprognosisandtherapeuticresponsesofheadandnecksquamouscellcarcinoma
AT yangwenhan novelnecroptosisrelatedlncrnasignatureforpredictionofprognosisandtherapeuticresponsesofheadandnecksquamouscellcarcinoma
AT zhulei novelnecroptosisrelatedlncrnasignatureforpredictionofprognosisandtherapeuticresponsesofheadandnecksquamouscellcarcinoma
AT liuwanyu novelnecroptosisrelatedlncrnasignatureforpredictionofprognosisandtherapeuticresponsesofheadandnecksquamouscellcarcinoma
AT wangyudong novelnecroptosisrelatedlncrnasignatureforpredictionofprognosisandtherapeuticresponsesofheadandnecksquamouscellcarcinoma